Forbes

Trump appeared last week poised to introduce a new proposal aimed at both temporarily prolonging premium tax credits and reforming the ACA. But Republicans rebuffed it.

December 1 was World AIDS Day. For the first time since this global event was established in 1988, the United States government declined to observe it.

The WHO formally recognized Cannabinoid Hyperemesis Syndrome (CHS) October 1, 2025, distinguishing the syndrome from other gastrointestinal disorders.

Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike to confront a pivotal question.

By piloting a six-year demonstration project called WISeR, Medicare is implementing an AI-led prior authorization policy that is already in place in Medicare Advantage.

The CDC's vaccine advisory committee is set to meet December 4th. A doctor explains what will be discussed and the public health consequences that could result.

Akido Labs' AI-enabled care model aims to dramatically expand healthcare capacity. Here, we explore how it works and what it signals for healthcare’s future.

These young entrepreneurs, researchers and doctors are improving care, empowering patients and making healthcare more efficient.

The anti-malarial GanLum's Phase 3 data highlight the drug’s potential to further combat the threat of antimalarial drug resistance in Africa.

CMS announced in Nov. a new drug payment model called GENEROUS, designed to make most-favored nation prices available to state Medicaid programs via manufacturer rebates.

A deeper look at how ACA premium subsidies work, why pandemic-era expansions accelerated costs and how defined-contribution subsidies could make Obamacare more affordable

A new chapter is unfolding for patients with sickle cell disease and beta-thalassemia: breakthroughs in gene regulation are transforming how these conditions are treated.

The U.S. will not commemorate World AIDS Day this year. This action, along with recent federal funding cuts, could contribute to a resurgence of HIV/AIDS.

Medicare beneficiaries spent $1.7 billion out of pocket on the 15 drugs. The negotiated price reductions may save beneficiaries $685 million in out-of-pocket costs.

Sachin Jain’s annual list of health industry predictions covering managed care, hospitals, pharma, digital health, and entrepreneurship.